## HIGHLIGHTS

- **2367** Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

- **2369** Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice
  Bruce J. Giantonio
  See related articles, p. 2394, 2400, 2408, 2416, 2424, and 2430

- **2372** Amplifying the Voice of the Whispering Cancer
  Neesha C. Dhani
  See related article, p. 2549

- **2375** New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma
  Bradley A. McGregor and Guru P. Sonpavde
  See related article, p. 2560

### CCR Drug Updates

- **2378** FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

### Review

- **2383** IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy
  Alvaro Teijeira, Saray Garasa, Maria C. Ochoa, Maria Villa, Irene Olivera, Assunta Cirella, Inaki Eguren-Santamaria, Pedro Berraondo, Kurt A. Schalper, Carlos E. de Andrea, Miguel F. Sannamed, and Ignacio Melero

## Perspectives

- **2394** Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement
  See related commentary, p. 2369

- **2400** Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Washout Period and Concomitant Medication Work Group
  See related commentary, p. 2369

- **2408** Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group
  See related commentary, p. 2369

- **2416** Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group
  Alexander I. Spira, Mark D. Stewart, Suzanne Jones, Elaine Chang, Anitra Fielding, Nicole Richie, Laura S. Wood, Michael A. Thompson, Lee Jones, Abhilasha Nair, Brandon A. Mahal, and David E. Gerber
  See related commentary, p. 2369
TABLE OF CONTENTS

2424 Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group
See related commentary, p. 2369

2430 Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations
See related commentary, p. 2369

2435 CLINICAL TRIALS: TARGETED THERAPY
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

2442 A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study
Mariko D. DeWire, Christine Fuller, Olivia Campagne, Tong Lin, Haitao Pan, Tina Young Poussaint, Patricia A. Baxter, Eugene J. Hwang, Andrew Bukowski, Kathleen Norris, Lindsey Hoffman, Angela J. Waanders, Matthias A. Karajannis, Clinton F. Stewart, Arzu Onar-Thomas, Maryam Fouladi, and Ira J. Dukel

2447 Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer

2467 CLINICAL TRIALS: IMMUNOTHERAPY
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

2481 Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy
Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers

Kelly L. Harms, Lili Zhao, Bryan Johnson, Xiaoming Wang, Shannon Caruskodon, Nallasivam Palanisamy, Daniel R. Rhodes, Rahul Mannan, Josh N. Vo, Jae Eun Choi, May P. Chan, Douglas R. Fullen, Rajiv M. Patel, Javed Siddiqui, Vincent T. Ma, Steven Hrycaj, Scott A. McLean, Tasha M. Hughes, Christopher K. Bichakjian, Scott A. Tomlins, and Paul W. Harms

The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer

Paolo Manca, Salvatore Corallo, Adele Busico, Sara Lonardi, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Matteo Clavarezza, Valeria Smiroldo, Gianluca Tomassello, Roberto Murialdo, Andrea Sartore-Bianchi, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Federica Palermo, Federica Perrone, Elena Tamborini, Michele Prisciandaro, Alessandra Paparini, Maria Di Bartolomeo, Federica Morano, and Filippo Pietrantonio

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study


High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9


Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition

Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzen, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, and Eric B. Haura

Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer

Lara Paracchini, Luca Beltrame, Tommaso Grassi, Alessia Inglesi, Robert Fruscio, Fabio Landoni, Davide Ippolito, Martina Delle Marchette, Mariachiara Paderno, Marco Adorni, Marta Jaconi, Chiara Romualdi, Maurizio D’Incalci, Giulia Siravegna, and Sergio Marchini

See related commentary, p. 2372

Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma


See related commentary, p. 2375

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors


Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer


Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification

ABOUT THE COVER

The cover shows an on-treatment biopsy taken from a patient with metastatic microsatellite stable colorectal cancer treated with combined PD-L1/CTLA-4 inhibition and targeted radiotherapy to a liver metastasis. Multiplex immunofluorescence staining demonstrates increased infiltration of CD8⁺ (white)/PD-1⁺ (green)/Ki-67⁺ (red) cells with treatment. Cytokeratin (purple) highlights malignant cells. For details, see the article by Monjazeb and colleagues on page 2470 of this issue.